Adaptimmune Therapeutics Plc
(NASDAQ : ADAP)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-1.25%194.271.3%$534.93m
GILDGilead Sciences, Inc.
-0.39%65.910.9%$358.61m
ALXNAlexion Pharmaceuticals, Inc.
-4.86%102.602.0%$309.75m
ILMNIllumina, Inc.
1.18%301.783.5%$306.80m
BIIBBiogen Inc.
-1.43%235.301.3%$295.43m
CELGCelgene Corporation
0.11%98.711.3%$288.69m
SRPTSarepta Therapeutics, Inc.
-2.38%82.8614.6%$174.60m
AAgilent Technologies, Inc.
0.55%76.821.6%$174.30m
VRTXVertex Pharmaceuticals Incorporated
-0.80%174.601.9%$173.15m
REGNRegeneron Pharmaceuticals, Inc.
-2.09%282.092.6%$168.99m
EXASExact Sciences Corporation
-1.70%105.0524.1%$132.89m
ACADACADIA Pharmaceuticals Inc.
-3.78%40.9913.9%$110.63m
INCYIncyte Corporation
-1.39%78.002.5%$84.52m
BMRNBioMarin Pharmaceutical Inc.
0.65%75.494.3%$71.69m
ALDRAlder Biopharmaceuticals, Inc.
0.32%18.7610.2%$64.14m

Company Profile

Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.